
What happened
CorMedix CEO Joseph Todisco bought 80,000 shares of CorMedix Inc. (NASDAQ: CRMD), lifting his direct stake in the company's common stock. The purchase matters because it adds to the CEO's direct ownership and gives holders a current read on how much stock he kept personally.
Todisco's Form 4 says the purchase happened on Nov. 13, and he signed the report on Nov. 16, after the trades were done. The filing lists him as a director, chief executive officer and 10% owner, and it shows common stock rather than derivative securities. After the purchase, he held 854,749 shares directly.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Common shares bought | 80,000 shares | SEC Form 4 | |
| Weighted average price | $4.89 | SEC Form 4 | |
| Purchase value | about $391,200 | SEC Form 4 | |
| Shares held after trade | 854,749 shares | SEC Form 4 | |
| Purchase as share of pre-trade holding | 10.3% | Calculated from SEC Form 4 |
Read more: CorMedix (CRMD) company research
Why it matters
He paid a weighted average $4.89 a share, and the transaction was about $391,200 in total across the reported fills. The report says the shares changed hands in multiple trades at prices from $4.85 to $5.00, so the weighted average is the cleanest single price.
OptimistFi has argued that CorMedix can become a profitable, cash-generating specialty pharmaceutical company by combining DefenCath's unique dialysis-market position with Melinta's hospital-focused infectious-disease portfolio. Todisco's buy strengthens that view slightly because the CEO added to his stake, and holders can see that commitment in direct ownership.
The purchase equals about 10.3% of Todisco's pre-trade holding of 774,749 shares, which makes it a meaningful addition to his own exposure. That makes the buy more than a token fill, but it is still only one transaction and a narrow signal for investors. The best caveat is that the filing condenses multiple fills into one weighted average, so investors should read it as a narrow ownership signal.
For holders, that makes the filing useful as a clean ownership update and a straightforward read on the CEO's stake.
Stock perps: every US stock that trades as a perpetual future, by leverage, live
What's next
CorMedix's next quarterly report is the next observable check on whether the company backs this insider move with business progress. A stronger report would make the purchase look more in step with management's outlook, while a weaker one would leave it as a standalone buy.
More from OptimistFi
From OptimistFi Perps
- Futures calculator: liquidation price, PnL and fees by exchange
- Perp funding rates live: what longs and shorts pay on every venue
- Stock perps vs tokenized stocks: how US shares trade around the clock
- Weekend market prices: US stock indexes, gold and oil now
- Perps news: leveraged stocks, gold, FX and crypto on-chain
- Prop firms that fund crypto and stock perps traders: rules, prices and payouts
Sources
- SEC Form 4 — Joseph Todisco reported a purchase of CorMedix common stock on Nov. 13, 2026, executed in multiple trades at $4.85 to $5.00.
Explore OptimistFi research on CorMedix Inc.: https://optimistfi.com/stocks/CRMD
Browse CorMedix Inc. company coverage and explore the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
Find available research on the CorMedix Inc. company page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
